Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06350539 · ClinicalTrials.gov registry record
Personalized Models for Cancer Research
A clinical trial of Solid Tumor, Adult, sponsored by New York Stem Cell Foundation Research Institute.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06350539: Recruiting study of Solid Tumor, Adult, sponsored by New York Stem Cell Foundation Research Institute.
NCT06350539 is a study of Solid Tumor, Adult that is actively recruiting participants, run by New York Stem Cell Foundation Research Institute. The registered enrollment target is 500 participants, above the 184-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (172% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06350539, a study of Solid Tumor, Adult, is actively recruiting participants, sponsored by New York Stem Cell Foundation Research Institute.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to personalized medicine approaches that will help to realize the promise of precision medicine for oncology.
Primary Outcome
NYSCF will establish patient specific tumor models known as organoids. Organoids are three dimensional cell culture laboratory models with self-organizing capabilities and long-term expansion potential that recapitulate the tissue they are derived from at the histological, molecular, and phenotypic level. We will create organoids from each subject sample collected. Primary outcome measure is successful growth of organoids from individual tumor samples.
Conditions Studied
Interventions
- OTHER Biological Sample Collection
Study Locations (1)
New York
- New York Stem Cell Foundation Research Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2034-02-15 |
What NCT06350539 shows while recruiting
NCT06350539 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 184-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (172% higher).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which Biological Sample Collection is the first listed.
NCT06350539 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06350539 about?
NCT06350539 is a clinical study titled "Personalized Models for Cancer Research". The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to personalized medicine approaches that will help to realize the promise of precision medicine for oncology.
What is the current status of trial NCT06350539?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-02-15. Estimated completion is 2034-02-15.
What conditions does trial NCT06350539 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT06350539?
The interventions under investigation include: Biological Sample Collection (OTHER).
Who is sponsoring clinical trial NCT06350539?
This trial is sponsored by New York Stem Cell Foundation Research Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06350539 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06350539's enrollment target sits among peer trials
500 4th of 72 higher than 69 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
RECRUITING
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
RECRUITING · NA
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI